Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novo Nordisk A/S (NVO) vs Under Armour Inc Class A (UA) Price & Performance

Novo Nordisk A/STrade
Under Armour Inc Class ATrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Under Armour Inc Class A — how do they compare? Novo Nordisk A/S trades at $46.19 (market cap $207.85B), while Under Armour Inc Class A trades at $5.14 (market cap $2.26B). The key difference: Novo Nordisk A/S is far larger — about 92× Under Armour Inc Class A's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.

NVOUA
Market Cap
$207.85B$2.26B
Sector
HealthConsumer Cyclical
52-Week High
$63.98$7.88
52-Week Low
$35.29$3.96
Enterprise Value
$222.55B$3.24B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.

Under Armour Inc Class A

Under Armour (UA) trades at $5.14, down 9.43% amid bearish technical signals and negative profitability metrics. The company reported Q1 2026 revenue of $1.1 billion, missing expectations, and lowered its fiscal 2027 revenue outlook due to soft consumer demand in North America and Asia-Pacific. Despite beating EPS estimates in two of the last three quarters, negative net income margin of -9.99% and declining revenue trends highlight ongoing challenges.

The stock faces significant headwinds from deteriorating fundamentals and negative cash flow, though analyst consensus remains cautiously optimistic with 38.8% buy ratings. Key risks include continued revenue declines, competitive pressure, and execution challenges in the turnaround strategy. The current valuation at 0.45 P/S offers potential value if management can stabilize operations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO

About Under Armour Inc Class A

Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.

Read more on UA